Cancer Drug Could Be Repurposed to Fight Alzheimer’s and Memory Loss

We often hear about "drug repurposing"—taking a medicine already approved for one condition and finding it works for another. It is a faster, safer way to find new treatments because we already know the drug is safe for humans. A new study published this week in Alzheimer's Research & Therapy suggests we might have found a powerful new candidate for Alzheimer’s disease, hiding in plain sight on the cancer ward. The drug is called CI-994. It was originally developed to stop tumour growth, but researchers have discovered it has a remarkable "dual-action" ability to repair the brain's memory networks. The "Double Whammy" Effect Alzheimer’s is complex, often caused by multiple failures in the brain at once. This study found that CI-994 tackles two of the biggest problems simultaneously: Unlocking Genes (HDAC Inhibition): In conditions like Alzheimer’s, the brain’s "memory genes" can get locked down and stop working. CI-994 acts like a key, inhibiting a group of proteins (called HDACs) that normally clamp these genes shut. By blocking these proteins, the drug "opens up" the DNA, allowing the brain to switch its memory and learning processes back on. Boosting Brain Signals (Wnt Signaling): The study also found—for the first time—that this drug activates a crucial communication pathway called "Wnt/β-catenin." This pathway is essential for keeping synapses (brain connections) healthy. In Alzheimer's, this signal often goes quiet; CI-994 turns the volume back up. Why This Matters for Parkinson’s Too While this specific study focused on Alzheimer’s, the implications for Parkinson’s are significant. Both conditions share similar features, particularly the buildup of toxic proteins (like tau) and the loss of cognitive function. The study showed that CI-994 significantly reduced the phosphorylation of tau—the "tangles" that choke brain cells. Since cognitive decline is a major fear for many with Parkinson’s, a drug that can protect memory and synapse health is a beacon of hope for all neurodegenerative conditions. The researchers used advanced "brain organoids" (mini-brains grown from patient stem cells) to prove this works on human tissue, not just in mice. Because CI-994 is an orally active drug (a pill, not an injection) that has already been in clinical trials for cancer, the path to testing it in patients with memory loss could be much shorter than starting from scratch.